HOME >> BIOLOGY >> NEWS
ORNL wins four R&D 100 awards, pushing total to 116

OAK RIDGE, Tenn., July 2, 2003 -- Researchers at the Department of Energy's Oak Ridge National Laboratory have won four R&D awards from R&D Magazine, which since 1963 has given the awards for the 100 most significant innovations of the year.

"All of us at ORNL are extremely proud of our staff for winning these awards," said ORNL Director Bill Madia. "The award is among the most coveted in the world of scientific research, and winning it brings prestige to both the researcher and the laboratory."

ORNL's total of 116 awards is second only to General Electric. The following inventions received honors:

RAMiTS: Raman Integrated Tunable Sensor, developed and submitted by Tuan Vo-Dinh, Joel Mobley, Brain Cullum and David Stokes of the Life Sciences Division, and Alan Wintenberg and Steven Frank of the Engineering Science and Technology Division. Robert Maples of RIS of Knoxville is a co-developer.

RAMiTS is a compact, "point-and-shoot," fully integrated, battery-operated Raman monitor and is based on solid-state acoustooptic tunable filter technology. Outside the laboratory, this device can perform qualitative analysis of chemical and biological samples in seconds. RAMiTS can identify hundreds of substances, including toxic chemicals, by-products from explosives, biomedical markers, pharmaceuticals and illicit drugs. RAMiTS also could help revolutionize sensing applications such as environmental monitoring, medical diagnostics and homeland security, researchers said.

MicroTrapMS, developed and submitted jointly by Michael Ramsey, William Whitten and Peter Reilly of the Chemical Sciences Division; Oleg Kornienko, postdoctoral ORNL fellow; and Protasis Corp. of Marlboro, Mass.

MicroTrapMS is a highly miniaturized ion trap mass spectrometer that is based on ORNL patented technology. The product can be used for applications from on-line screening for toxins in municipal watersheds to detecting hazardous substances at airport chec
'"/>

Contact: Ron Walli
wallira@ornl.gov
865-576-0226
DOE/Oak Ridge National Laboratory
2-Jul-2003


Page: 1 2 3

Related biology news :

1. Scientists receive awards, give lectures at the ASBMB/IUBMB meeting
2. ORNL adds three R&D 100s to DOE lab-leading total
3. NIH consensus panel confirms effectiveness of total knee replacement
4. Sleep debts accrue when nightly sleep totals six hours or fewer
5. AFAR announces 189 new grants for aging research totalling $10 million
6. Whitaker makes largest individual grants ever totaling more than $30 million

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ORNL wins four awards pushing total

(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: